Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.54 |
| ▸ | CTSS | P25774 | 11/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431997 | 0.83 | CTSK (0.45) | CTSKCTSSCTSLCTSB | |
| SCHEMBL5459590 | 0.83 | CTSK (0.45) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12733104 | 0.82 | EPHX1 (0.48) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL1414447 | 0.82 | EPHX1 (0.48) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL3122584 | 0.82 | EPHX1 (0.48) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL2702388 | 0.82 | EPHX1 (0.48) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL8137772 | 0.81 | EPHX1 (0.47) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL8282037 | 0.81 | EPHX1 (0.47) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL13622689 | 0.81 | EPHX1 (0.47) | CTSKCTSSEPHX1HDAC4HDAC1 | |
| SCHEMBL3125943 | 0.81 | EPHX1 (0.46) | CTSKCTSSEPHX1HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| US-7026505-B2 | Method of treating tinnitus | WARNER-LAMBERT COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1475371-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (= GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1469841-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6518289-B1 | Especially irritable bowel syndrome | PFIZER, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | CTSK 3647/4885CTSS 3957/4885EPHX1 2236/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CTSK 717/4885CTSS 1033/4885EPHX1 2819/4885 |
| US-20060100281-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRB2 | CTSK 3588/4885CTSS 3984/4885EPHX1 2321/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CTSK 717/4885CTSS 1033/4885EPHX1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.